Article
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Cancer research - 1 May 2010
Lazzara Matthew J, Lane Keara, Chan Richard, Jasper Paul J, Yaffe Michael B, Sorger Peter K, Jacks Tyler, Neel Benjamin G, Lauffenburger Douglas A
Abstract excerpt
Most non-small cell lung cancers (NSCLC) display elevated expression of epidermal growth factor receptor (EGFR), but response to EGFR kinase inhibitors is predominantly limited to NSCLC harboring EGFR-activating mutations. These mutations are associated with increased activity of survival pathways, including phosphatidylinositol 3-kinase/AKT and signal transducer and activator of transcription 3/5. We report that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.